Cryoport Inc
F:CKX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cryoport Inc
F:CKX
|
US |
|
S
|
Secom Co Ltd
XMUN:XSC
|
JP |
|
S
|
Snam SpA
XBER:SNM
|
IT |
|
C
|
China Carbon Neutral Development Group Ltd
HKEX:1372
|
HK |
|
H
|
Hartford Financial Services Group Inc
LSE:0J3H
|
US |
|
Heineken NV
AEX:HEIA
|
NL |
|
P
|
PetroChina Co Ltd
F:PC6A
|
CN |
|
Cryoport Inc
NASDAQ:CYRX
|
US |
|
North American Construction Group Ltd
NYSE:NOA
|
CA |
|
A
|
Alexandria Real Estate Equities Inc
LSE:0HCH
|
US |
|
Jardine Matheson Holdings Ltd
OTC:JMHLY
|
HK |
|
Endesa SA
OTC:ELEZF
|
ES |
|
GAIL (India) Ltd
OTC:GAILF
|
IN |
|
GrowGeneration Corp
NASDAQ:GRWG
|
US |
Cryoport Inc
Cryoport helps life-science companies move delicate biological materials that must stay frozen or tightly temperature-controlled. It ships things like cell and gene therapy materials, reproductive medicine samples, and other high-value biologics using specialized containers, tracking tools, and logistics support designed for cryogenic transport. Its customers are mainly drug developers, biotech and pharmaceutical companies, fertility clinics, hospitals, and research groups. Cryoport makes money by charging for shipping services, equipment and containers, temperature-monitoring tools, and related support services that keep shipments secure and traceable from origin to destination. What makes the business different is that it sits in a very sensitive part of the healthcare supply chain. These are not ordinary parcels; a damaged shipment can ruin irreplaceable materials or a patient dose. That gives Cryoport a role as a specialized logistics partner for products that need strict handling, documentation, and chain-of-custody control.
Cryoport helps life-science companies move delicate biological materials that must stay frozen or tightly temperature-controlled. It ships things like cell and gene therapy materials, reproductive medicine samples, and other high-value biologics using specialized containers, tracking tools, and logistics support designed for cryogenic transport.
Its customers are mainly drug developers, biotech and pharmaceutical companies, fertility clinics, hospitals, and research groups. Cryoport makes money by charging for shipping services, equipment and containers, temperature-monitoring tools, and related support services that keep shipments secure and traceable from origin to destination.
What makes the business different is that it sits in a very sensitive part of the healthcare supply chain. These are not ordinary parcels; a damaged shipment can ruin irreplaceable materials or a patient dose. That gives Cryoport a role as a specialized logistics partner for products that need strict handling, documentation, and chain-of-custody control.
Top line: Cryoport said first-quarter revenue was $47.8 million, up 16% year over year, with strength across both Services and Products.
Guidance: Management raised full-year 2026 revenue guidance to $192 million to $196 million, citing stronger-than-expected start to the year and better visibility.
Profitability: Adjusted EBITDA from continuing operations improved by $2.2 million year over year, and management still expects positive adjusted EBITDA in the second half of 2026.
Commercial growth: Commercial cell and gene therapy revenue grew 26% to $9.1 million, and Cryoport now supports 21 commercial therapies after Rocket Pharmaceutical’s FDA approval.
Pipeline: The company supported a record 766 global clinical trials, including 91 in Phase III, and said it expects 10 BLA or MAA filings and up to 8 new therapy approvals in 2026.
New initiatives: IntegriCell shipped its first cryopreserved clinical trial patient materials, while new facilities in Paris, Houston, Belgium, and Santa Ana are expected to support longer-term growth.
